Project Grant F32AI197522
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $2.178 million on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate chemosensory mechanisms by which the African malaria mosquito Anopheles gambiae detects and responds to human body odor to facilitate malaria transmission. The research identifies volatile organic compounds in human scent signatures correlated with mosquito attraction and...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $273,337 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of persistent sodium currents in modulating mosquito sensory behavior and spatial repellency to transfluthrin, a volatile pyrethroid insecticide. The research focuses on understanding how transfluthrin-based spatial emanators—recommended by the World Health Organization for malaria...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $198,728 on February 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate visual-olfactory learning and integration in the yellow fever mosquito, Aedes aegypti. The research addresses how mosquitoes combine visual and olfactory sensory cues to locate and feed on hosts. Specific Aim 1 examines multimodal learning and memory of visual and olfactory stimuli...
- The National Institute of Allergy and Infectious Diseases, operating under the Department of Health and Human Services, awarded Kansas State University $238,247 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on larval immunity in the African malaria mosquito Anopheles gambiae. The project identifies molecular interactions that regulate melanization through proteolytic activation of phenoloxidase in An. gambiae larvae, with the...
- The National Institute of Allergy and Infectious Diseases awarded Kansas State University $738,183 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the immunoregulatory protease network that controls melanization in Anopheles gambiae, the African malaria mosquito vector. The research identifies molecular interactions that regulate phenoloxidase activation and melanization cascade proteases, with the objective of understanding how protease...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Dakota $207,810 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish the duration of mosquitocidal efficacy for two isoxazoline drugs, fluralaner and lotilaner, when ingested by relevant vertebrate species involved in the transmission of West Nile virus and malaria. The project focuses on determining how long a single dose of isoxazoline drug can continue...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a Project Grant of $426,938 effective August 1, 2025 through July 31, 2027 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research focuses on evaluating combined inhibition strategies against Plasmodium falciparum merozoite invasion into erythrocytes, a critical target for antimalarial drug development. The project will assess the...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $667,643 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a malaria intelligence system and mobile decision-support application for malaria prevention and control in Kenya. The project addresses insecticide-resistant mosquito populations and outdoor biting behavior that have emerged from widespread use of long-lasting insecticide-treated...
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $192,500 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of enteroendocrine cells in West Nile Virus replication and transmission in Culex tarsalis mosquitoes. The research comprises two aims: Aim 1 will use dissociated midgut cells from colonized mosquitoes infected with barcoded WNV, flow cytometry, and sequencing to quantify the...
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $525,789 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify bacterial isolates and communities that influence male life history traits and mating success in Aedes aegypti mosquitoes. The funded research experimentally colonizes mosquitoes with multiple candidate bacterial communities and determines the impact of different communities on male longevity,...
The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $152,600 on October 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the neural basis of spatial repellency in the malaria mosquito Anopheles gambiae. The research identifies active ingredients in lemongrass oil species (Cymbopogon citratus, Cymbopogon flexuosus, and Cymbopogon pendulus) that drive spatial repellency and determines the underlying neural mechanisms. Work in Aim 1 characterizes the repellency and mode of action for individual chemical components across the three lemongrass species. Aim 2 investigates which olfactory sensory neurons respond to these active ingredients using transgenic mosquitoes expressing a calcium-sensing fluorescent marker, then identifies the odorant receptors expressed by olfactory receptor neurons via microdissection and RNA-seq and evaluates their individual responses. The project addresses the limited options for spatial repellents—which act at distance to prevent mosquitoes from entering areas such as homes—by clarifying chemosensory pathways that enable screening and optimization of repellent candidates. Understanding spatial repellency mechanisms supports synergistic use of repellents alongside other mosquito-control strategies to prevent transmission of mosquito-borne diseases. Performance takes place in Baltimore, Maryland. The period of performance runs from October 15, 2026 through August 31, 2029. The assistance type is a Project Grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $76.3k | 4/17/26 | ||
| Not listed | $76.3k | 4/17/26 | ||
| Not listed | $0 | 4/17/26 |